panaxadiol has been researched along with Acute Confusional Senile Dementia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, F; Guo, HY; Jia, Y; Lee, JJ; Li, J; Liu, P; Liu, Z; Pang, L; Quan, YS; Quan, ZS; Shen, QK; Sui, HH | 1 |
| Kong, L; Liang, X; Lin, Y; Shi, Y; Xiao, H; Yang, J; Yao, Y | 1 |
2 other study(ies) available for panaxadiol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
In vitro and in vivo biological evaluation of newly synthesized multi-target 20(R)-panaxadiol derivatives for treating Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Donepezil; Drug Design; Mice; Neuroprotective Agents | 2022 |
Panaxadiol inhibits synaptic dysfunction in Alzheimer's disease and targets the Fyn protein in APP/PS1 mice and APP-SH-SY5Y cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Line; Disease Models, Animal; Ginsenosides; Humans; Memory; Memory Disorders; Mice; Mice, Transgenic; Phosphorylation; Proteins; Proto-Oncogene Proteins c-fyn; Receptors, N-Methyl-D-Aspartate; Signal Transduction; Synapses | 2019 |